论文部分内容阅读
目的:评价希罗达(Xeloda)治疗国人转移性乳腺癌的疗效及其安全性。方法:2001年6月至2002年8月,共入选76例转移性乳腺癌病人。所有病人均予希罗达2 500mg/m~2/天,分早晚两次,饭后30分钟内口服,连服14天,间歇7天,即每个治疗周期为21天;至少治疗2周期。结果:76例中,1例完全缓解,25例部分缓解。病情稳定34例(44.7％),疾病进展为 15例(19.7％)。总有效率为 34.2％。肿瘤控制率(CR+PR+SD)为 78.9％。毒性反应 Ⅰ/Ⅱ级主要为手足综合征 19例(25.0％)、恶心13例(17.1％)和腹泻12例(15.8％); Ⅲ级主要为恶心2例(2.6％)、呕吐2例(2.6％)、血小板减少2例(2.6％)、GOT升高2例(2.6％)及头晕1例(1.3％),无Ⅳ级毒性。结论:口服希罗达治疗国人复治的转移性乳腺癌疗效较高,耐受性好,可以推广应用。
Objective: To evaluate the efficacy and safety of Xeloda in treating metastatic breast cancer in Chinese people. Methods: From June 2001 to August 2002, 76 patients with metastatic breast cancer were enrolled. All patients were given Xeloda 2 500mg / m ~ 2 / day, minutes and nights, orally 30 minutes after a meal, and even served 14 days, intermittent 7 days, that is, each treatment period of 21 days; at least 2 cycles of treatment . Results: Among the 76 cases, 1 was completely relieved and 25 patients were partially relieved. 34 cases (44.7%) had stable disease and 15 cases (19.7%) had disease progression. The total effective rate was 34.2%. Tumor control rate (CR + PR + SD) was 78.9%. Nineteen patients (25.0%) had hand-foot syndrome, nausea in 13 (17.1%) and diarrhea in 12 patients (15.8%). Grade Ⅲ mainly included nausea in 2 patients (2.6%), vomiting in 2 patients 2.6%), thrombocytopenia in 2 cases (2.6%), GOT increased in 2 cases (2.6%) and dizziness in 1 case (1.3%). Conclusion: Xeloda oral rectal cancer treatment of metastatic breast cancer patients with high efficacy, good tolerance, can be widely applied.